PF-Atlas › Treatments › NAD+/NMN Supplementation

NAD+/NMN Supplementation

Restores NAD+ levels depleted in aging lungs — supports sirtuin-mediated DNA repair and mitochondrial function

Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Phase I/II
Evidence level
Level 3 (Phase I)
Mechanism class
Restores NAD+ levels depleted in aging lungs — supports sirtuin-mediated DNA repair and mitochondrial function
Timeline
1-2 years
Risk profile
Low
Developer
Multiple
Key researchers
Multiple

Overview

NAD+ declines with age and in IPF lung tissue. NMN/NR supplementation restores levels. Supports SIRT1/3 activity protecting against fibrosis. Low risk, available as supplement. Multiple aging clinical trials ongoing.

How NAD+/NMN Supplementation fits into IPF treatment

NAD+/NMN Supplementation is classified as Level 3 (Phase I) at the Phase I/II stage. Explore how it compares to other options and where it sits in the development pipeline:

NAD drug profileRestores NAD+ levels depleted in aging lungs — supports sirtuin-mediated DNA repair and mitochondrial functionClinical trialsDrug pipelineResearch

Other IPF treatments

Nerandomilast / JascaydInhaled Treprostinil / TyvasoAdmilparant / BMS-986278Rentosertib / ISM001-055AI Knowledge GraphuPAR-CAR-T Senolytic Immunotherapy
Medical disclaimer. This page summarizes published research and PF-Atlas model output about NAD+/NMN Supplementation for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.